Treatment with Galantamine in patients with cognitive impairment following cerebral infarction

Abstract

Evaluation of Cognitive Function Improvement with Galantamine in Patients with Post-Stroke Cognitive Impairment: This study aims to evaluate the effectiveness of Galantamine in improving cognitive function in patients with cognitive impairment following a stroke. The study also aims to identify factors that may influence the treatment outcomes in these patients. The study was conducted on 245 patients admitted to the Neurology-Orthopedic Department of Can Tho General Hospital. The results showed that the improvement rate in cognitive function for patients under 60 years old was 53.8% compared to 46.2% in the group over 60 years old. There were 84 patients completed 12 weeks of treatment. The mean MMSE score at 12 weeks after treatment was 19.82, while the mean MMSE score at 4 weeks post-stroke was 19.57. The difference in mean MMSE scores between the assessment points was statistically significant. Factors related to treatment outcomes included age, educational level, baseline cognitive impairment, and subcortical lesions. The rate of patients responding to Galantamine treatment was 20.2%. The reported side effects of the medication included nausea and vomiting (7.1%), diarrhea (3.6%), and anorexia. Galantamine is a therapeutic option for maintaining and improving cognitive impairment in stroke patients to enhance cognitive function. It is recommended to use Galantamine for treating cognitive impairment following a stroke in patients under 60 years old, with higher educational levels, mild cognitive impairment, and subcortical lesions.